On November 6, 2025, Vigonvita Life Sciences (stock code: 2630.HK) globally issued 17,597,800 H shares and listed on the Main Board of the Hong Kong Stock Exchange. The issuance price was HKD 33.37 per share, raising over HKD 580 million (before exercising the over-allotment option).

On December 22, 2025, Simcere Zaiming announced that it has entered into an exclusive global licensing agreement, excluding Greater China, with French company Ipsen for an antibody-drug conjugate (ADC) SIM0613, which has the potential to be best-in-class.

The lead partner for this project was lawyer ZHAO, Hao (Gerry).